HGF and neoplasm: One example of the use of DARPins for immuno‐oncology purposes is that of MP0250, a drug candidate that binds and inhibits vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), thus altering the tumor microenvironment (Baird et al., 2021).